References in periodicals archive ?
Veracyte (NASDAQ: VCYT) is a genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions.
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions.
Also higher after reporting quarterly results were Veracyte (VCYT) and PGT, Inc.
(NASDAQ: VCYT) has received regulatory authorisation from the New York State Department of Health to offer the Envisia Genomic Classifier for patients in the state effective immediately, the company said.
Also higher after reporting quarterly results was Veracyte (VCYT), which gained 7%.
ALSO LOWER: Veracyte (VCYT) down 4.5% after equity offering...
(NASDAQ: VCYT) has entered into a long-term strategic collaboration with Johnson and Johnson Innovation LLC and the Lung Cancer Initiative at Johnson and Johnson (NYSE: JNJ) to advance the development and commercialisation of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable, the company said.
(NASDAQ: VCYT) has presented data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease, including idiopathic pulmonary fibrosis, without the need for surgery, the company said.
(NASDAQ: VCYT) has received new findings from six studies reinforcing the "real world" performance of the next-generation Afirma Genomic Sequencing Classifier and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th annual meeting of the American Thyroid Association, the company said.
- Early user-experience data from three independent studies demonstrate that South San Francisco, California-based genomic diagnostics company Veracyte, Inc.'s (NASDAQ: VCYT) next-generation Afirma genomic sequencing classifier (GSC) significantly increases the number of patients who can avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original, market-leading Afirma gene expression classifier (GEC), the company said.
(NASDAQ: VCYT) has presented new data at the annual meeting of the Endocrine Society that suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original Afirma test, the company said.
(NASDAQ: VCYT) has presented data demonstrating the accuracy of identification of BRAF V600E and parathyroid tissue through new classifiers developed in conjunction with the next-generation Afirma Genomic Sequencing Classifier, the company said.
Acronyms browser ?
Full browser ?